Dicerna nabs speedy review voucher for leading RNAi drug

RNA biotech Dicerna has nabbed a priority review voucher as part of its new rare pediatric disease designation for leading drug nedosiran.

The RNAi drug is in the clinic for primary hyperoxaluria (PH) types 1, 2 and 3 and is Dicerna’s most advanced asset using the biotech’s so-called GalXC RNAi tech platform.